/CMPS
CMPS Stock - COMPASS Pathways plc
Healthcare|Medical - Care FacilitiesNASDAQ
$6.37+2.58%
+$0.16 (+2.58%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.93
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.42
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+135.5%upside
Target: $15.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CMPS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.31 – $6.43
TARGET (TP)$15.00
STOP LOSS$5.86
RISK/REWARD1:16.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.94
52W High$7.13
52W Low$2.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-112,871 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-178,205,000 | $-136,919,000 | $-110,403,000 | $-83,221,000 | $-51,792,783 |
| Net Income | $-155,122,000 | $-118,464,000 | $-91,505,000 | $-71,742,000 | $-60,803,335 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-1.68 |
Company Overview
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$21
Average Target
↑ 229.7% Upside
Now
$6
Low
$21
Average
$34
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 10th 2025 | Oppenheimer | Upgrade | Outperform | $15 |
| June 23rd 2025 | Evercore ISI | Downgrade | In-line | $6← $11 |
| February 27th 2025 | Stifel | Initiation | Buy | $11 |
| July 23rd 2024 | RBC Capital Mkts | Initiation | Outperform | $23 |
| April 1st 2024 | Morgan Stanley | Initiation | Overweight | $30 |
| December 12th 2023 | Deutsche Bank | Initiation | Buy | $16 |
| November 21st 2022 | Berenberg | Resumed | Buy | $33 |
| November 1st 2022 | Loop Capital | Initiation | Buy | $34 |
Earnings History & Surprises
CMPSBeat Rate
50%
Last 18 quarters
Avg Surprise
-0.7%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-0.38
Q4 2025
EPS Surprise History
Q1 24
-43.2%
$-0.53vs$-0.37
Q2 24
-5.8%
$-0.55vs$-0.52
Q3 24
-5.7%
$-0.56vs$-0.53
Q4 24
+6.7%
$-0.56vs$-0.60
Q1 25
-1.6%
$-0.63vs$-0.62
Q2 25
+6.4%
$-0.44vs$-0.47
Q3 25
-2.7%
$-0.38vs$-0.37
Q4 25
+5.0%
$-0.38vs$-0.40
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.43 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.40 | $-0.38 | +5.0% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-0.37 | $-0.38 | -2.7% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.47 | $-0.44 | +6.4% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.62 | $-0.63 | -1.6% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $-0.60 | $-0.56 | +6.7% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.53 | $-0.56 | -5.7% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.52 | $-0.55 | -5.8% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-0.37 | $-0.53 | -43.2% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.50 | $-0.67 | -34.0% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.69 | $-0.62 | +10.1% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.73 | $-0.57 | +21.9% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.65 | $-0.73 | -12.3% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.66 | $-0.43 | +34.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.61 | $-0.50 | +18.0% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.68 | $-0.50 | +26.5% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.48 | $-0.61 | -27.1% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.50 | $-0.38 | +24.0% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.33 | $-0.44 | -33.3% | ✗ MISS |
Latest News
Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $11
📈 PositiveBenzinga•Nov 5, 2025, 06:04 PM
CORRECTION: Compass Pathways Q3 Adj. EPS $(0.38) Beats $(0.39) Estimate
📈 PositiveBenzinga•Nov 4, 2025, 02:38 PM
CMPS stock has given up its prior loss. COMPASS Pathways shares were trading lower.
➖ NeutralBenzinga•Nov 4, 2025, 02:38 PM
COMPASS Pathways shares are trading lower. The company announced it is accelerating commercialization readiness plans by 9 to 12 months and completed its COMP006 trial enrollment and meeting with the FDA on marketing application submission strategies for COMP260 in treatment resistant depression.
➖ NeutralBenzinga•Nov 4, 2025, 02:07 PM
Compass Pathways Said Its Accelerating Commercialization Readiness Plans By 9-12 Months. It Has Completed COMP006 Trial Enrollment And Meeting With FDA On Marketing Application Submission Strategies For COMP360 In Treatment Resistant Depression, Including Potential Rolling Submission
📈 PositiveBenzinga•Nov 4, 2025, 11:38 AM
Compass Pathways Q3 EPS $(1.44) Misses $(0.38) Estimate
📉 NegativeBenzinga•Nov 4, 2025, 11:31 AM
NeuroKaire Enters R&D Collaboration With COMPASS Pathways To Advance Precision Psychiatry And Neurology
📈 PositiveBenzinga•Oct 30, 2025, 12:38 PM
Psychedelic stocks gain after positive remarks from GOP Senator in North Carolina
📈 PositiveSeeking Alpha•Oct 14, 2025, 06:06 PM•Also: , ,
'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment
📈 PositiveBenzinga•Oct 13, 2025, 05:28 PM•Also: , ,
BTIG Maintains Buy on Compass Pathways, Raises Price Target to $14
📈 PositiveBenzinga•Oct 13, 2025, 05:17 PM
'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment
➖ NeutralBenzinga•Oct 2, 2025, 03:03 PM•Also: , ,
'Massachusetts Lawmakers Approve Bill To Create Psychedelic Therapy Pilot Program' - Marijuana Moment
📈 PositiveBenzinga•Sep 12, 2025, 04:30 PM•Also: , ,
Compass Pathways Says Open-Label Phase 2 Study Shows Single 25 Mg COMP360 Psilocybin Dose Was Well Tolerated, With No Serious Adverse Events Observed, And Indicated Both Rapid And Durable Improvement In Symptoms From Baseline Observed Out To 12 Weeks Following Single Administration
📈 PositiveBenzinga•Sep 2, 2025, 10:35 AM
Compass Pathways Publishes Results From Open-Label Phase 2 Study Evaluating Safety And Tolerability Of Single-Dose Of 25 Mg Of Investigational COMP360 Synthetic Psilocybin Treatment In 22 Patients With Post-Traumatic Stress Disorder
➖ NeutralBenzinga•Sep 2, 2025, 10:33 AM
'Military To Start Testing Service Members For The Psychedelic Psilocin, Memo Shows' - Marijuana Moment
➖ NeutralBenzinga•Aug 28, 2025, 06:16 PM•Also: , ,
Shares of psychedelic companies are trading higher after a GOP senator stated he's "confident" that under the Trump administration, lawmakers will help secure alternative treatment options for military veterans, including access to psychedelic medicine.
📈 PositiveBenzinga•Aug 25, 2025, 06:53 PM•Also: , ,
'GOP Senator Is 'Confident' Psychedelics Access Will Expand Under Trump, Saying Many Veterans Speak To Him About The Benefits' - Marijuana Moment
📈 PositiveBenzinga•Aug 22, 2025, 07:53 PM•Also: , ,
'U.S. Senate Committee To Hold Hearing On Benefits Of Psychedelics For Military Veterans'- Marijuana Moment
📈 PositiveBenzinga•Aug 21, 2025, 06:35 PM•Also: , ,
Compass plummets as late-stage data on psychedelic asset for depression disappoints
📉 NegativeSeeking Alpha•Jun 23, 2025, 03:48 PM
Frequently Asked Questions about CMPS
What is CMPS's current stock price?
COMPASS Pathways plc (CMPS) is currently trading at $6.37 per share. The stock has moved +2.58% today.
What is the analyst price target for CMPS?
The average analyst price target for CMPS is $15.00, based on 1 analyst.
What sector is COMPASS Pathways plc in?
COMPASS Pathways plc operates in the Healthcare sector, specifically within the Medical - Care Facilities industry. The company is traded on the NASDAQ exchange.
What is CMPS's market cap?
COMPASS Pathways plc has a market capitalization of $0.61 billion, making it a small-cap company.
Does CMPS pay dividends?
No, COMPASS Pathways plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAVNS
Avanos Medical, Inc.
$11.67
Mkt Cap: $0.5B
CYH
Community Health Systems, Inc.
$3.26
Mkt Cap: $0.5B
EHAB
Enhabit, Inc.
$9.56
Mkt Cap: $0.5B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
SNDA
Sonida Senior Living, Inc.
$32.95
Mkt Cap: $0.6B
TALK
Talkspace, Inc.
$3.55
Mkt Cap: $0.6B
VREX
Varex Imaging Corporation
$12.29
Mkt Cap: $0.5B
Explore stocks similar to CMPS for comparison